Newsroom
-
The 30-year-old female founder at the forefront of a billion-dollar bet on CRISPR gene editing
CNBCLearn More -
Venture Investment in Crispr Gene Editing Spurs Innovation, Hunt for IP
Wall Street JournalLearn More -
Bayer jumps on board Mammoth’s ultra-small CRISPR tech with sights set first on liver disease
Endpoints NewsLearn More -
Bayer to pay CRISPR-focused Mammoth Biosciences $40 million for gene editing research
STAT NewsLearn More -
Bayer and Mammoth Biosciences to collaborate on novel gene editing technology
Business WireLearn More -